ホーム › びまん性大細胞型B細胞リンパ腫 › ミネソタ州
ミネソタ州におけるびまん性大細胞型B細胞リンパ腫の臨床試験
ミネソタ州内の拠点で、びまん性大細胞型B細胞リンパ腫に関する16件の研究が参加者を募集しています。
ミネソタ州内の都市
公式研究テキスト（英語）
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 他3件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06649812Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Mayo Clinic Health Systems-Mankato, Mankato
- Mayo Clinic in Rochester, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT03418038A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Rochester, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Minnesota Oncology Hematology (MNO) ( Site 8004), Burnsville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06890884A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Mayo Clinic - Rochester, Rochester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06091865A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Mayo Clinic - Rochester, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Mayo Clinic - Rochester, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- University of Minnesota Medical Center, Minneapolis
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT06500273Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
- University of Minnesota/Masonic Cancer Center, Minneapolis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT06536049Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Mayo Clinic Rochester, Rochester
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Mayo Clinic, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Mayo Clinic Health Systems-Mankato, Mankato
- Mayo Clinic in Rochester, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/01/28更新 · NCT06834373Auto Stem Cell Transplant for Lymphoma Patients
- Masonic Cancer Center, University of Minnesota, Minneapolis
被験者募集中第2相
75歳以下 · 全性別 · 2025/11/04更新 · NCT03125642Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- Essentia Health Hibbing Clinic, Hibbing
- 他2件
被験者募集中第2相
18歳以上 · 全性別 · 2025/10/20更新 · NCT05890352Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- Mayo Clinic in Rochester, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2024/09/26更新 · NCT06238648ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。